MRNA vs. BIIB, BNTX, ARGX, GILD, NBIX, TECH, QGEN, RGEN, CRSP, and DNLI
Should you be buying Moderna stock or one of its competitors? The main competitors of Moderna include Biogen (BIIB), BioNTech (BNTX), argenx (ARGX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Qiagen (QGEN), Repligen (RGEN), CRISPR Therapeutics (CRSP), and Denali Therapeutics (DNLI). These companies are all part of the "biological products, except diagnostic" industry.
Moderna (NASDAQ:MRNA) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, community ranking, risk, media sentiment and institutional ownership.
Biogen received 1578 more outperform votes than Moderna when rated by MarketBeat users. Likewise, 71.89% of users gave Biogen an outperform vote while only 57.77% of users gave Moderna an outperform vote.
Biogen has a net margin of 12.07% compared to Moderna's net margin of -115.82%. Biogen's return on equity of 14.83% beat Moderna's return on equity.
75.3% of Moderna shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 15.7% of Moderna shares are owned by company insiders. Comparatively, 0.6% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Moderna had 8 more articles in the media than Biogen. MarketBeat recorded 36 mentions for Moderna and 28 mentions for Biogen. Moderna's average media sentiment score of 0.60 beat Biogen's score of 0.29 indicating that Moderna is being referred to more favorably in the media.
Moderna has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, Biogen has a beta of -0.01, meaning that its stock price is 101% less volatile than the S&P 500.
Biogen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.
Moderna currently has a consensus target price of $126.46, suggesting a potential downside of 4.85%. Biogen has a consensus target price of $288.46, suggesting a potential upside of 25.11%. Given Biogen's stronger consensus rating and higher probable upside, analysts plainly believe Biogen is more favorable than Moderna.
Summary
Biogen beats Moderna on 13 of the 18 factors compared between the two stocks.
Get Moderna News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
